BIOCRYST PHARMACEUTICALS, INC. Capital Expenditures
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Capital Expenditures of $343.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-13.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2020-03-13
- BIOCRYST PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for fiscal 2019 was $343.00K, a 6.28% decline from fiscal 2018.
- BIOCRYST PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for fiscal 2018 was $366.00K, a 11.59% increase from fiscal 2017.
- BIOCRYST PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for fiscal 2017 was $328.00K.
| Period end | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|
| 2019-12-31 | $343.00K 10-K · filed 2020-03-13 |
| 2018-12-31 | $366.00K 10-K · filed 2020-03-13 |
| 2017-12-31 | $328.00K 10-K · filed 2020-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |